Long-term bone marrow damage after chemotherapy for acute myeloid leukaemia does not improve with time.
Thirteen patients with acute myeloid leukaemia (AML) who had been in unmaintained complete remission for at least 5 years following successful chemotherapy, were studied by marrow culture techniques regularly for periods of up to 5 years. In 10 patients, short-term clonal assay revealed the incidence of granulocyte-macrophage progenitor cells (GM-CFC) to be at the lower limit of the normal range; but three showed wide fluctuations in GM-CFC numbers. Moreover the generation of GM-CFC in long-term bone marrow culture (LTBMC) was impaired in eight of nine evaluable patients. These results suggest that, despite normal blood counts, impairment of haemopoiesis persists in patients who are long-term survivors of AML, and this does not improve with the passage of time.
Chang
J
J
Department of Haematology, Paterson Laboratory, Christie Hospital, Manchester.
Geary
C G
CG
Testa
N G
NG
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006098:Granulocytes / Q000473:pathology; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors; D014410:Tumor Stem Cell Assay